Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$19.95 USD
-0.05 (-0.25%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $19.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.95 USD
-0.05 (-0.25%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $19.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
New Strong Buy Stocks for October 11th
by Zacks Equity Research
PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.
Humana (HUM) Boosts Healthcare Choices for MA Members in Denver
by Zacks Equity Research
Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.
4 Stocks That Exhibit Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
by Zacks Equity Research
Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $12.66, moving -0.78% from the previous trading session.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $13.53, marking a +1.42% move from the previous day.
Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed at $13.15 in the latest trading session, marking a +0.15% move from the prior day.
Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
by Zacks Equity Research
Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.
Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Catalyst (CPRX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $11.83, marking a +1.37% move from the previous day.
Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum
by Zacks Equity Research
Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the Week article.
Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.
5 Stocks to Keep a Tab on for Solid Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).
Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Catalyst's (CPRX) Q1 Earnings Lag, Sales Boost Revenues
by Zacks Equity Research
Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $16.60, moving -0.12% from the previous trading session.
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.